Gastrointestinal Medicines · LP-082
Metoclopramide Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-082Gastrointestinal Medicines
- Generic identity
- MetoclopramideTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-082
- Generic identity
- Metoclopramide
- Presentation
- Tablet
- Catalogue strength
- 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Metoclopramide.
- Dosage form: Tablet.
- Catalogue strength / concentration: 10 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Gastrointestinal Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Tablet composition, score/alteration instructions and controlled release character if any.
- Approved duration, age eligibility, contraindications and tardive-dyskinesia/extrapyramidal warning wording.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
A 2026 DailyMed metoclopramide tablet label retains a boxed tardive-dyskinesia warning and duration limitations, supporting a strong label-specific safety hold.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg | Tablet | — | Blister 10 x 10 tablets | Do not infer long-term use, paediatric eligibility or tablet-specific dosing from ingredient identity. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Metoclopramide is an antiemetic and prokinetic medicine with dopamine-antagonist activity. It is used in selected clinical situations involving nausea, vomiting or impaired gastric movement. Neurologic adverse effects constrain its use and treatment duration. This educational ingredient profile does not establish Luang Pharma approved indications, pediatric eligibility or a suitable regimen; current local prescribing information and individualized review are essential. Current national restrictions apply.
Clinical context and therapeutic role
The cause of nausea or vomiting should be assessed before selecting a medicine that changes gastrointestinal motility. Obstruction, bleeding, dehydration or another serious illness can require different management. A professional should review Parkinson’s disease, seizures, previous movement disorders and interacting medicines. Duration restrictions and age-specific recommendations vary by jurisdiction. Persistent symptoms should be reassessed rather than treated with repeated unsupervised courses, particularly if involuntary movements or significant restlessness develop.
Selected safety context
Acute dystonia, akathisia and other movement disorders can occur, and prolonged exposure increases concern about tardive dyskinesia. New abnormal movements, muscle stiffness, fever or altered consciousness needs urgent assessment. Drowsiness may impair driving. Parkinson’s disease, epilepsy and gastrointestinal obstruction are important contraindication considerations. Interactions with antipsychotics, dopaminergic and serotonergic medicines require review. A person should not extend treatment or combine antiemetics without professional advice.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: MetoclopramideArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Metoclopramide tablets — external label exampleArchived source classification: US official drug label example | Source revision recorded: Major label changes February 2026; Archived access check: 2026-09-11 | External comparator supporting safety-context review; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-082.
Professional enquiries
Request product-specific evidence for LP-082.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.